|
|
||||||||
RESEARCH AND PRACTICE |
Marion M. Lee, Jeffrey S. Chang, and Margaret R. Wrensch are with the Department of Epidemiology and Biostatistics, University of California, San Francisco. Bradly Jacobs is with the Osher Center for Integrative Medicine, Department of Medicine, University of California, San Francisco.
Correspondence: Requests for reprints should be sent to Marion M. Lee, PhD, MPH, Department of Epidemiology and Biostatistics, University of California, Box 0560, San Francisco, CA 94143-0560 (e-mail: mlee{at}epi.ucsf.edu).
| INTRODUCTION |
|---|
|
|
|---|
| METHODS |
|---|
|
|
|---|
The questionnaire collected information on demographic characteristics; acculturation (country of birth and language spoken at home); family history of prostate cancer; participation in religious, recreational, professional, or other social groups; other illnesses; smoking status; alcohol consumption; exercise; types of conventional therapy undergone for prostate cancer; and types of CAM used for prostate cancer (Table 1
). Details on the types of CAM that were included were described in an earlier article.2
|
Logistic regression analyses were conducted to determine associations between covarying variables and CAM use (Table 2
). Variables that were significant at the P < .05 level and variables that had odds ratios of 1.5 or more or of 0.5 or less in univariate analyses were entered into a multivariate logistic regression model to determine their relative importance in association with CAM use.
|
| RESULTS |
|---|
|
|
|---|
Table 1
shows percentages of men using specific types of CAM by ethnicity. As can be seen, prevalence rates of CAM use and types of CAM used varied greatly according to ethnicity. Table 2
presents data on factors associated with CAM use. It is evident that factors influencing CAM use varied by ethnicity as well.
| DISCUSSION AND CONCLUSIONS |
|---|
|
|
|---|
To our knowledge, this is the first study of CAM therapy use among prostate cancer patients to involve significant percentages of non-English-speaking (15%) and Asian (20%) participants. When we examined members of each ethnic group separately, we found differences in correlates of CAM use. Among members of different ethnic groups, it is likely that use is influenced by individual cultural norms and experiences.16
This study involved several limitations. First, the study population, from the ethnically diverse San Francisco Bay Area, may not be comparable to samples from other parts of the country with different ethnic compositions. Second, we included only 3 Asian ethnic groups, and thus the results may not be representative of all Asian ethnic groups in the United States. Finally, because the study was cross sectional, the associations found may not reflect effects of 1 factor on another.
It is important for physicians to ascertain whether their patients are using CAM, in that many CAM therapies may affect the bodys physiological functioning and be associated with drug interactions.1719 In addition, previous studies have shown that CAM use may be related to emotional distress.13,20 Initiating discussions regarding CAM use and reasons for use may be a good way for physicians to assess patients emotional status and to provide emotional support.
In light of the ethnic differences in correlates of CAM use revealed in our study, future research should examine patterns of CAM use and reasons associated with use among different racial/ethnic groups. Such ethnicity-specific data will be important in helping physicians understand motivations behind CAM use and in facilitating effective discussions with patients.
| Acknowledgments |
|---|
We thank Scarlett Lin, Jade Lin, Vance Ingalls, Veronica Gov, Sue Zhou, Guillermo Torano, Jeffrey Chu, Maria Diaz-Mendez, Michael Hsu, Garrett Tichauer, Casey Hart, Rita Leung, and Christine Choy for their assistance in various stages of the study.
Human Participant Protection
Because the data for this study were gathered through telephone interviews, written consent was not obtained. However, we did obtain verbal consent via telephone from each participant before we began the interview process. This process was approved by the Committee on Human Subject Research at the University of California, San Francisco.
| Footnotes |
|---|
Accepted for publication June 4, 2002.
| References |
|---|
|
|
|---|
2. Lee MM, Lin SS, Wrensch MR, Adler SR, Eisenberg D. Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst. 2000;92:4247.
3. Sparber A, Bauer L, Curt G, et al. Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum. 2000;27:623630.[Medline]
4. Von Gruenigen VE, White LJ, Kirven MS, Showalter AL, Hopkins MP, Jenison EL. A comparison of complementary and alternative medicine use by gynecology and gynecologic oncology patients. Int J Gynecol Cancer. 2001;11:205209.[Medline]
5. Adler SR, Fosket JR. Disclosing complementary and alternative medicine use in the medical encounter: a qualitative study in women with breast cancer. J Fam Pract. 1999;48:453458.[Medline]
6. Nam RK, Fleshner N, Rakovitch E, et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol. 1999;161:15211524.[Medline]
7. Kao GD, Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer. 2000;88:615619.[Medline]
8. Lippert MC, McClain R, Boyd JC, Theodorescu D. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer. 1999;86:26422648.[Medline]
9. Lubeck DP, Litwin MS, Flanders SC, Henning JM, Carroll PR. Use of complementary and alternative medicine (CAM) treatments among a cohort of newly diagnosed prostate cancer patients: data from CapSUREO [abstract]. Abstract Book Assoc Health Serv Res. 1999;16:37.
10. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:25052514.
11. Gotay CC, Hara W, Issell BF, Maskarinec G. Use of complementary and alternative medicine in Hawaii cancer patients. Hawaii Med J. 1999;58:9498.[Medline]
12. Crocetti E, Crotti N, Feltrin A, Ponton P, Geddes M, Buiatti E. The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer. 1998;34:324328.
13. Paltiel O, Avitzour M, Peretz T, et al. Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol. 2001;19:24392448.
14. Leung JM, Dzankic S, Manku K, Yuan S. The prevalence and predictors of the use of alternative medicine in presurgical patients in five California hospitals. Anesth Analg. 2001;93:10621068.
15. Astin JA. Why patients use alternative medicine: results of a national study. JAMA. 1998;279:15481553.
16. Maskarinec G, Shumay DM, Kakai H, Gotay CC. Ethnic differences in complementary and alternative medicine use among cancer patients. J Altern Complementary Med. 2000;6:531538.[Medline]
17. Smolinske SC. Dietary supplement-drug interactions. J Am Med Womens Assoc. 1999;54:191192, 195.
18. Ang-Lee MK, Moss J, Yuan CS. Herbal medicine and perioperative care. JAMA. 2001;286:208216.
19. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 1998;339:785791.
20. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999;340:17331739.
This article has been cited by other articles:
![]() |
C. M. Velicer and C. M. Ulrich Vitamin and Mineral Supplement Use Among US Adults After Cancer Diagnosis: A Systematic Review J. Clin. Oncol., February 1, 2008; 26(4): 665 - 673. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Cassileth, G. E. Deng, J. E. Gomez, P. A. S. Johnstone, N. Kumar, and A. J. Vickers Complementary Therapies and Integrative Oncology in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 340S - 354S. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. I Ortiz, K. M Shields, K. A Clauson, and P. G Clay Complementary and Alternative Medicine Use Among Hispanics in the United States Ann. Pharmacother., June 1, 2007; 41(6): 994 - 1004. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tascilar, F. A. de Jong, J. Verweij, and R. H. J. Mathijssen Complementary and Alternative Medicine During Cancer Treatment: Beyond Innocence Oncologist, July 1, 2006; 11(7): 732 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. K. Dy, L. Bekele, L. J. Hanson, A. Furth, S. Mandrekar, J. A. Sloan, and A. A. Adjei Complementary and Alternative Medicine Use by Patients Enrolled Onto Phase I Clinical Trials J. Clin. Oncol., December 1, 2004; 22(23): 4810 - 4815. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Struthers and V. S. Eschiti The Experience of Indigenous Traditional Healing and Cancer Integr Cancer Ther, March 1, 2004; 3(1): 13 - 23. [Abstract] [PDF] |
||||
![]() |
B. R. Cassileth and G. Deng Complementary and Alternative Therapies for Cancer Oncologist, February 1, 2004; 9(1): 80 - 89. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |